EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy

NCT00391534 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped Low recruitment rate

Conditions

Partial Epilepsy

Interventions

DRUG: modified release formulation of oxcarbazepine (OXC MR)
DRUG: immediate release formulation of oxcarbazepine (OXC IR)

Sponsor

Desitin Arzneimittel GmbH

Collaborators

[object Object]